^
    Back
    Association details:
    Biomarker:BCR-ABL1 fusion
    Cancer:B Acute Lymphoblastic Leukemia
    Drug:imatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, PDGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    REGIMENS FOR RELAPSED OR REFRACTORY Ph-POSITIVE B-ALL…Other Recommended Regimens...TKI (dasatinib, imatinib, ponatinib, nilotinib, or bosutinib)
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Acute Lymphocytic Leukemia)
    New
    Excerpt:
    Gleevec is a kinase inhibitor indicated for the treatment of:...Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)...Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2021
    Title:

    3003 - In vitro and in vivo model for evaluation of novel therapeutic agents in patient -derived acute B-lymphoblastic leukemia (B-ALL)

    Published date:
    03/10/2021
    Excerpt:
    Interestingly, BCR-ABL-ve models were resistant to imatinib and BCR-ABL+ve sensitive. 
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2020
    Title:

    Establishment of a Patient-Derived Acute B Lymphoblastic Leukemia (B-ALL)Ex Vivo and In Vivoplatform for Evaluation of Novel Therapeutic Agents

    Published date:
    11/04/2020
    Excerpt:
    ...BCR-ABL+ve sensitive, when treated with small molecule inhibitor imatinib.
    DOI:
    https://doi.org/10.1182/blood-2020-143383